Bringing New Vision to the Fight Against Cancer

Joining the FightWWW.DSI.COM

Drawing on our experienceOur legacy includes the development of several first-in-class oncology products:

• The first chemotherapy to demonstrate survival benefits in colorectal cancer

• The first natural-type interferon beta preparation for the treatment of glioblastoma and skin cancer

Partnering with expertsWe are continuing to build a world-class research and development organization with the acquisition of companies that make cutting-edge contributions to the understanding and treatment of cancer and conduct innovative preclinical trials. Our biotechnology group now includes U3 Pharma GmbH and Plexxikon Inc among others and is working to generate a wide range of groundbreaking compounds.

A growing oncology pipelineOur oncology pipeline continues to grow and currently includes both small molecules and monoclonal antibodies with novel targets in both solid and liquid tumors.

Who is joining the fight? How are we joining the fight?

Making medicines that make a differenceWe take our responsibility to our patients seriously and are committed to being a trusted partner, helping patients improve their health. Today, our products help patients in 56 countries around the world.

Joining the fightWe are applying our dedication and expertise to the discovery and development of novel oncology agents with the goal of delivering first-in-class and best-in-class cancer treatments that address unmet medical needs.

Daiichi Sankyo: a heritage of innovation

Daiichi Sankyo (Die-eee-chee San KEE OH) is a global company with over 31,000 employees and a heritage of scientific discovery that spans more than 110 years. Established in 2006 with the merger of Daiichi Pharmaceutical Co., Ltd. and Sankyo Co., Ltd., 2 leading century-old pharmaceutical companies, our legacy of innovation includes:

• Discovering epinephrine more than a century ago

• Discovering vitamin B1 drugs

• Discovering the first HMG-CoA reductase inhibitor and the statin class of drugs

• Discovering troglitazone for glucose control and the glitazone class of drugs

Dr. Jokichi Takamine, a renowned Japanese chemist and our company’s (Sankyo) first president, funded the gift of 3000 cherry trees from Tokyo to Washington, DC in 1912 as a sign of appreciation and friendship between the 2 nations. The National Cherry Blossom Festival—Washington DC’s and the nation’s greatest springtime event—annually celebrates this gift and its symbol of enduring friendship between the citizens of Japan and the United States.

Joining the FightWWW.DSI.COM

Daiichi Sankyo and all affiliates

Daiichi Sankyo is joining the fight

Daiichi Sankyo, Inc. · Two Hilton Court · Parsippany, NJ 07054©2012 Daiichi Sankyo, Inc. All rights reserved. Printed in US 2012 DSON12100012

Bringing new vision to the fight against cancer• Our heritage of scientific discovery spans

more than 110 years

• We developed the first chemotherapy to demonstrate survival benefits in colorectal cancer and the first natural-type interferon beta preparation for the treatment of glioblastoma and skin cancer

• Our oncology pipeline continues to grow and currently includes both small molecules and monoclonal antibodies with novel targets in both solid and liquid tumors

Joining the FightWWW.DSI.COM